STAT News – Biotech
STAT+: Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections
An experimental, long-acting treatment for eczema from Apogee Therapeutics induced skin and itch relief comparable to current, widely used medicines but with less frequent injections, a study reported Monday by the company showed.
The new data will need to be confirmed in larger clinical trials, but if the results hold up, Apogee’s drug could offer patients with moderate-to-severe atopic dermatitis a more convenient treatment option over Regeneron and Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
In the mid-stage study, 75% of participants injected once every three months with Apogee’s drug, called zumilokibart, maintained at least a 75% improvement in the extent and severity of skin lesions — a metric dubbed EASI-75 — at one year. Eighty-five percent of participants injected with zumilokibart once every six months maintained the same EASI-75 skin response at one year.